Cargando…
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer
Knowledge of the basic mechanisms of the immune system as it relates to cancer has been increasing rapidly. These developments have accelerated the translation of these advancements into medical breakthroughs for many cancer patients. The immune system is designed to discriminate between self and no...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039332/ https://www.ncbi.nlm.nih.gov/pubmed/24883190 http://dx.doi.org/10.1186/2051-1426-2-14 |
_version_ | 1782318471770537984 |
---|---|
author | Raval, Raju R Sharabi, Andrew B Walker, Amanda J Drake, Charles G Sharma, Padmanee |
author_facet | Raval, Raju R Sharabi, Andrew B Walker, Amanda J Drake, Charles G Sharma, Padmanee |
author_sort | Raval, Raju R |
collection | PubMed |
description | Knowledge of the basic mechanisms of the immune system as it relates to cancer has been increasing rapidly. These developments have accelerated the translation of these advancements into medical breakthroughs for many cancer patients. The immune system is designed to discriminate between self and non-self, and through genetic recombination there is virtually no limit to the number of antigens it can recognize. Thus, mutational events, translocations, and other genetic abnormalities within cancer cells may be distinguished as “altered-self” and these differences may play an important role in preventing the development or progression of cancer. However, tumors may utilize a variety of mechanisms to evade the immune system as well. Cancer biologists are aiming to both better understand the relationship between tumors and the normal immune system, and to look for ways to alter the playing field for cancer immunotherapy. Summarized in this review are discussions from the 2013 SITC Primer, which focused on reviewing current knowledge and future directions of research related to tumor immunology and cancer immunotherapy, including sessions on innate immunity, adaptive immunity, therapeutic approaches (dendritic cells, adoptive T cell therapy, anti-tumor antibodies, cancer vaccines, and immune checkpoint blockade), challenges to driving an anti-tumor immune response, monitoring immune responses, and the future of immunotherapy clinical trial design. |
format | Online Article Text |
id | pubmed-4039332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40393322014-05-31 Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer Raval, Raju R Sharabi, Andrew B Walker, Amanda J Drake, Charles G Sharma, Padmanee J Immunother Cancer Review Knowledge of the basic mechanisms of the immune system as it relates to cancer has been increasing rapidly. These developments have accelerated the translation of these advancements into medical breakthroughs for many cancer patients. The immune system is designed to discriminate between self and non-self, and through genetic recombination there is virtually no limit to the number of antigens it can recognize. Thus, mutational events, translocations, and other genetic abnormalities within cancer cells may be distinguished as “altered-self” and these differences may play an important role in preventing the development or progression of cancer. However, tumors may utilize a variety of mechanisms to evade the immune system as well. Cancer biologists are aiming to both better understand the relationship between tumors and the normal immune system, and to look for ways to alter the playing field for cancer immunotherapy. Summarized in this review are discussions from the 2013 SITC Primer, which focused on reviewing current knowledge and future directions of research related to tumor immunology and cancer immunotherapy, including sessions on innate immunity, adaptive immunity, therapeutic approaches (dendritic cells, adoptive T cell therapy, anti-tumor antibodies, cancer vaccines, and immune checkpoint blockade), challenges to driving an anti-tumor immune response, monitoring immune responses, and the future of immunotherapy clinical trial design. BioMed Central 2014-05-14 /pmc/articles/PMC4039332/ /pubmed/24883190 http://dx.doi.org/10.1186/2051-1426-2-14 Text en Copyright © 2014 Raval et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Raval, Raju R Sharabi, Andrew B Walker, Amanda J Drake, Charles G Sharma, Padmanee Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer |
title | Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer |
title_full | Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer |
title_fullStr | Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer |
title_full_unstemmed | Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer |
title_short | Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer |
title_sort | tumor immunology and cancer immunotherapy: summary of the 2013 sitc primer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039332/ https://www.ncbi.nlm.nih.gov/pubmed/24883190 http://dx.doi.org/10.1186/2051-1426-2-14 |
work_keys_str_mv | AT ravalrajur tumorimmunologyandcancerimmunotherapysummaryofthe2013sitcprimer AT sharabiandrewb tumorimmunologyandcancerimmunotherapysummaryofthe2013sitcprimer AT walkeramandaj tumorimmunologyandcancerimmunotherapysummaryofthe2013sitcprimer AT drakecharlesg tumorimmunologyandcancerimmunotherapysummaryofthe2013sitcprimer AT sharmapadmanee tumorimmunologyandcancerimmunotherapysummaryofthe2013sitcprimer |